Literature DB >> 1371266

Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study.

R Jefferis1, C B Reimer, F Skvaril, G G de Lange, D M Goodall, T L Bentley, D J Phillips, A Vlug, S Harada, J Radl.   

Abstract

Following the 1st IUIS/WHO Collaborative Study of monoclonal anti-IgG subclass antibodies, a panel of WHO Specificity Reference Reagents (SRR) was established [Jefferis, R., et al. (1985) Immunol. Lett., 10, 223]. At the time, the hope was expressed that further reagents particularly for IgG2, and other allotypic specificities would become available which could be applied in a wide range of assay protocols. The 2nd study reports the evaluation of nineteen anti-subclass and seven anti-allotype monoclonal antibodies. The anti-IgG1 antibody HP6187 was equivalent in performance to the SRR. Others, that were not of the mouse IgG1 isotype, may be useful for particular applications. The anti-IgG2 antibody HP6200 could be a valuable addition to the WHO SRR; it is specific for an epitope in the Fab region but does not have the light chain bias of HP6014. Antibodies of putative allotype specificity exhibited the claimed specificity when used within protocols similar to those employed by the originating laboratory. It appears to be inherent in the nature of the epitopes (allotopes) recognized that it will take several years before reagents applicable to a wide range of techniques will become available.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371266     DOI: 10.1016/0165-2478(92)90141-a

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  16 in total

1.  Human Immunoglobulin Heavy Gamma Chain Polymorphisms: Molecular Confirmation Of Proteomic Assessment.

Authors:  Magalie Dambrun; Célia Dechavanne; Alexandra Emmanuel; Florentin Aussenac; Marjorie Leduc; Chiara Giangrande; Joëlle Vinh; Jean-Michel Dugoujon; Marie-Paule Lefranc; François Guillonneau; Florence Migot-Nabias
Journal:  Mol Cell Proteomics       Date:  2017-03-06       Impact factor: 5.911

2.  Standardization: who wants it?

Authors:  R Jefferis
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 3.  Human immunoglobulin allotypes: possible implications for immunogenicity.

Authors:  Roy Jefferis; Marie-Paule Lefranc
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

4.  Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination.

Authors:  K R Lottenbach; C M Mink; S J Barenkamp; E L Anderson; S M Homan; D C Powers
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.

Authors:  Niels Heemskerk; Mandy Gruijs; A Robin Temming; Marieke H Heineke; Dennis Y Gout; Tessa Hellingman; Cornelis W Tuk; Paula J Winter; Suzanne Lissenberg-Thunnissen; Arthur Eh Bentlage; Marco de Donatis; Marijn Bögels; Thies Rösner; Thomas Valerius; Jantine E Bakema; Gestur Vidarsson; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

6.  Gel test assay for IgG subclass detection by GM typing: application to hemolytic disease of the newborn.

Authors:  S J Alié-Daram; A Fournié; J M Dugoujon
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

7.  Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Authors:  C L Vermont; H H van Dijken; C J P van Limpt; R de Groot; L van Alphen; G P J M van Den Dobbelsteen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

8.  Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass.

Authors:  R R Taylor; D B Smith; V J Robinson; J S McBride; E M Riley
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

9.  Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass.

Authors:  Stephan von Gunten; David F Smith; Richard D Cummings; Stefan Riedel; Sylvia Miescher; Alexander Schaub; Robert G Hamilton; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2009-05-13       Impact factor: 10.793

10.  Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.

Authors:  Shigeru Iida; Reiko Kuni-Kamochi; Katsuhiro Mori; Hirofumi Misaka; Miho Inoue; Akira Okazaki; Kenya Shitara; Mitsuo Satoh
Journal:  BMC Cancer       Date:  2009-02-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.